Skip to main content
Erschienen in: Drugs 4/2021

01.03.2021 | AdisInsight Report

BNT162b2 mRNA COVID-19 Vaccine: First Approval

verfasst von: Yvette N. Lamb

Erschienen in: Drugs | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

BNT162b2 (Comirnaty®; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. BNT162b2 encodes the SARS-CoV-2 spike protein, the expression of which elicits immune responses against the antigen in recipients. In early December 2020, BNT162b2 received a temporary emergency use authorization (EUA) in the UK and, subsequently, a series of approvals or authorizations for emergency use in Bahrain, Canada, Mexico, Saudi Arabia and the USA. Soon after, BNT162b2 received conditional marketing authorizations in Switzerland (19 December 2020) and the EU (21 December 2020) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older. BNT162b2 is administered intramuscularly in a two-dose regimen. This article summarizes the milestones in the development of BNT162b2 leading to these first approvals for the prevention of COVID-19.
Literatur
1.
Zurück zum Zitat Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–27.CrossRef Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–27.CrossRef
2.
Zurück zum Zitat Rego GNA, Nucci MP, Alves AH, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines. 2020;8(3):1–44.CrossRef Rego GNA, Nucci MP, Alves AH, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines. 2020;8(3):1–44.CrossRef
3.
Zurück zum Zitat Abbasi J. COVID-19 and mRNA vaccines - first large test for a new approach. JAMA. 2020;324(12):1125–7.CrossRef Abbasi J. COVID-19 and mRNA vaccines - first large test for a new approach. JAMA. 2020;324(12):1125–7.CrossRef
4.
6.
7.
Zurück zum Zitat BioNTech. Pfizer and BioNTech provide data from German phase 1/2 study further characterizing immune response following immunization with lead COVID-19 vaccine candidate BNT162b2 [media release]. 14 Dec 2020. http://www.biontech.de. BioNTech. Pfizer and BioNTech provide data from German phase 1/2 study further characterizing immune response following immunization with lead COVID-19 vaccine candidate BNT162b2 [media release]. 14 Dec 2020. http://​www.​biontech.​de.
9.
Zurück zum Zitat US Food and Drug Administration. FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine [media release]. 11 Dec 2020. http://www.fda.gov. US Food and Drug Administration. FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine [media release]. 11 Dec 2020. http://​www.​fda.​gov.
10.
14.
Zurück zum Zitat World Health Organisation. WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access [media release]. 31 Jan 2020. http://www.who.int. World Health Organisation. WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access [media release]. 31 Jan 2020. http://​www.​who.​int.
15.
16.
Zurück zum Zitat Burki T. Equitable distribution of COVID-19 vaccines. Lancet. 2021;21(1):P33–4.CrossRef Burki T. Equitable distribution of COVID-19 vaccines. Lancet. 2021;21(1):P33–4.CrossRef
18.
Zurück zum Zitat Pfizer, BioNTech. Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development [media release]. 9 Apr 2020. http://www.pfizer.com. Pfizer, BioNTech. Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development [media release]. 9 Apr 2020. http://​www.​pfizer.​com.
21.
22.
23.
Zurück zum Zitat BioNTech, Fosun Pharma. BioNTech and Fosun Pharma to potentially supply 10 million doses of BioNTech's BNT162 mRNA-based vaccine candidate against SARS-CoV-2 to Hong Kong SAR and Macao SAR [media release]. 27 Aug 2020. http://www.biontech.de. BioNTech, Fosun Pharma. BioNTech and Fosun Pharma to potentially supply 10 million doses of BioNTech's BNT162 mRNA-based vaccine candidate against SARS-CoV-2 to Hong Kong SAR and Macao SAR [media release]. 27 Aug 2020. http://​www.​biontech.​de.
26.
Zurück zum Zitat Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv. 2020:2020.12.09.20245175. Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv. 2020:2020.12.09.20245175.
27.
Zurück zum Zitat Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;14:14. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;14:14.
28.
Zurück zum Zitat BioNTech. An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission [media release]. 8 Jan 2021. http://www.biontech.de. BioNTech. An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission [media release]. 8 Jan 2021. http://​www.​biontech.​de.
30.
Zurück zum Zitat Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;10:10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;10:10.
31.
Zurück zum Zitat CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51. CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51.
Metadaten
Titel
BNT162b2 mRNA COVID-19 Vaccine: First Approval
verfasst von
Yvette N. Lamb
Publikationsdatum
01.03.2021
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 4/2021
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-021-01480-7

Weitere Artikel der Ausgabe 4/2021

Drugs 4/2021 Zur Ausgabe